The Link between NAFLD and Metabolic Syndrome

Area of Science:

• Endocrinology
• Hepatology
• Cardiology

Background:

• Metabolic syndrome (MetS) involves cardiovascular and type 2 diabetes risk factors like impaired fasting glucose, low HDL-cholesterol, high triglycerides, and hypertension.
• Insulin resistance (IR), driven by visceral adiposity, is a primary cause of MetS, affecting even non-obese individuals.
• Visceral adiposity is closely linked to non-alcoholic fatty liver disease (NAFLD), creating a bidirectional relationship where each condition can cause or result from the other.

Purpose of the Study:

• To highlight the intricate relationship between metabolic syndrome and non-alcoholic fatty liver disease.
• To emphasize the role of insulin resistance and visceral adiposity in the pathogenesis of both conditions.
• To discuss current and novel therapeutic strategies and diagnostic tools for NAFLD.

Main Methods:

• Review of recent studies on MetS, IR, visceral adiposity, and NAFLD.
• Analysis of diagnostic criteria and biomarkers for MetS and NAFLD.
• Exploration of therapeutic interventions including lifestyle changes, surgery, and pharmacological agents.

Main Results:

• Visceral adiposity is a key effector in MetS pathology and is strongly associated with NAFLD.
• The increasing prevalence of obesity contributes to a rise in NAFLD incidence.
• Numerous non-invasive diagnostic tools for NAFLD are available, aiding early detection and prevention of complications.

Conclusions:

• MetS and NAFLD share common pathophysiological pathways, primarily driven by insulin resistance and visceral fat.
• Lifestyle interventions, bariatric surgery, and specific medications offer therapeutic potential for MetS and NAFLD.
• Early diagnosis of NAFLD using accessible tools is crucial for preventing progression to advanced liver disease.